scholarly journals Intradermal vaccination of adults with three low doses (2 µg) of recombinant hepatitis B vaccine. I. Seroconversion rate and adverse effects

2003 ◽  
Vol 98 (8) ◽  
pp. 1101-1107 ◽  
Author(s):  
José Luís da S Baldy ◽  
Maria do Carmo M Elisbão ◽  
Edson T Anzai ◽  
Rubens Pontello ◽  
Edna Maria V Reiche ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Adverse Effects ◽  
Seroconversion Rate ◽  
Hepatitis B Vaccine ◽  
Low Doses ◽  
Recombinant Hepatitis ◽  
Intradermal Vaccination

scholarly journals Intradermal vaccination of adults with three low doses (2 µg) of recombinant hepatitis B vaccine. II. Persistence of immunity and induction of immunologic memory

2003 ◽  
Vol 98 (8) ◽  
pp. 1109-1113 ◽  
Author(s):  
Maria do Carmo M Elisbão ◽  
José Luís da S Baldy ◽  
Ana Maria Bonametti ◽  
Edna Maria V Reiche ◽  
Helena K Morimoto ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Hepatitis B Vaccine ◽  
Low Doses ◽  
Immunologic Memory ◽  
Recombinant Hepatitis ◽  
Intradermal Vaccination

scholarly journals IMMUNOGENICITY OF LOW-DOSE INTRAMUSCULAR AND INTRADERMAL VACCINATION WITH RECOMBINANT HEPATITIS B VACCINE

1997 ◽  
Vol 39 (1) ◽  
pp. 15-20 ◽  
Author(s):  
Marília Dalva TURCHI ◽  
Celina Maria Turchi MARTELLI ◽  
Maria Lúcia FERRAZ ◽  
Antonio Eduardo SILVA ◽  
Divina das Dores de Paula CARDOSO ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Recombinant Dna ◽  
Standard Dose ◽  
Seroconversion Rate ◽  
Geometric Mean ◽  
Hepatitis B Vaccine ◽  
Antibody Concentration ◽  
Intradermal Vaccination ◽  
Group I ◽  
Significant Difference

The study is a randomized trial using recombinant DNA vaccine to determine whether an intramuscular 10 µg dose or intradermal 2 µg induces satisfactory anti-HBs levels compared to the standard dose of intramuscular 20 µg. participants were 359 healthy medical and nurse students randomly allocated to one of the three groups: Group I - IM 20 µg; Group II - IM 10 µg; Group III - ID 2 µg at 0, 1 and 6 months. Anti-HBs titres were measured after complete vaccine schedule by ELISA/Pasteur. Baseline variables were similar among groups and side effects were mild after any dose. Vaccinees in the IM-10 µg group had seroconversion rate and geometric mean titre (GMT 2344 IU L-1), not significant different from the IM-20 µg group (GMT 4570 IU L-1). On the contrary, 21.4% of the ID - 2 µg recipients mount antibody concentration below 10 IU L1 and GMT of 91 IU L-1, a statiscally significant difference compared with the standard schedule IM-20 µg (p < 0.001). A three dose regimen of half dosse IM could be considered an appropriate schedule to prevent hepatitis B in young health adults which is of relevance to the expansion of hepatitis B vaccine programme

Low Seroconversion with Hepatitis B Vaccination in Peritoneal Dialysis Patients

1996 ◽  
Vol 16 (4) ◽  
pp. 370-373 ◽  
Author(s):  
Abdul N. Khan ◽  
Judy Bernardini ◽  
Raymond M. Rault ◽  
Beth Piraino
Keyword(s):  
Peritoneal Dialysis ◽  
Hepatitis B ◽  
Outcome Measure ◽  
Seroconversion Rate ◽  
Hepatitis B Vaccine ◽  
The Other ◽  
Hepatitis B Vaccination ◽  
Recombinant Hepatitis ◽  
Dialysis Patients ◽  
Main Outcome Measure

Objective To compare seroconversion using hepatitis B vaccine between hemodialysis (HD) and peritoneal dialysis (PD) patients. Design Data on PD patients vaccinated were collected retrospectively for the period 1992 to 1995. The data on HD patients were collected prospectively from 1991 to 1994. Setting A university outpatient dialysis center. Participants All adult patients who received all four doses of hepatitis B vaccine while on dialysis were included (47 PD and 50 HD patients). Intervention Recombinant hepatitis B vaccine (Engerix), 40 μg IM was administered at 0, 1, 2, and 6 months. Main Outcome Measure Seroconversion was measured after completion of the vaccination series. Results 74% of the HD patients seroconverted compared to 53 % of PD patients (p = 0.03). Older, heavier patients compared to all the other patients had a lower seroconversion rate in both the HD patients (55 % vs. 78 %) and PD patients (38 % vs. 59 %) (p = 0.03). Conclusion The seroconversion rate to recombinant hepatitis B vaccine is lower in patients on PD than on HD for unclear reasons. Further studies are required to determine the etiology of this difference.

scholarly journals Long-term persistence of immunity after vaccination of pre-adolescents with low doses of a recombinant hepatitis B vaccine

2013 ◽  
Vol 9 (8) ◽  
pp. 1685-1690 ◽  
Author(s):  
Vladimir Gilca ◽  
Gaston De Serres ◽  
Nicole Boulianne ◽  
Donald Murphy ◽  
Manale Ouakki ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Hepatitis B Vaccine ◽  
Low Doses ◽  
Recombinant Hepatitis

Antibody and immune memory persistence after vaccination of preadolescents with low doses of recombinant hepatitis B vaccine

2010 ◽  
Vol 6 (2) ◽  
pp. 212-218 ◽  
Author(s):  
Vladimir Gilca ◽  
Gaston De Serres ◽  
Nicole Boulianne ◽  
Philippe De Wals ◽  
Donald Murphy ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Hepatitis B Vaccine ◽  
Immune Memory ◽  
Low Doses ◽  
Recombinant Hepatitis ◽  
Memory Persistence

Immunogenicity of low doses of recombinant hepatitis B vaccine in young males

Vaccine ◽  
1988 ◽  
Vol 6 (4) ◽  
pp. 328-330 ◽  
Author(s):  
C. Tsakalakis ◽  
S.C. Richardson ◽  
A. Roumeliotou-Karayannis ◽  
G. Papaevangelou
Keyword(s):  
Hepatitis B ◽  
Hepatitis B Vaccine ◽  
Low Doses ◽  
Recombinant Hepatitis ◽  
Young Males
Sign in / Sign up

Export Citation Format

Share Document